Whittier Trust Co. cut its stake in Haleon plc (NYSE:HLN – Get Rating) by 37.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 27,365 shares of the company’s stock after selling 16,674 shares during the quarter. Whittier Trust Co.’s holdings in Haleon were worth $219,000 at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. Tompkins Financial Corp purchased a new position in shares of Haleon in the fourth quarter valued at $31,000. CKW Financial Group purchased a new position in shares of Haleon in the third quarter valued at $26,000. Whittier Trust Co. of Nevada Inc. purchased a new position in Haleon during the third quarter worth about $28,000. Assetmark Inc. purchased a new position in Haleon during the third quarter worth about $29,000. Finally, Hudock Inc. purchased a new position in Haleon during the third quarter worth about $30,000. 6.67% of the stock is currently owned by hedge funds and other institutional investors.
Haleon Trading Up 3.9 %
HLN opened at $8.97 on Friday. The stock has a 50-day moving average price of $8.08 and a 200-day moving average price of $7.36. Haleon plc has a 12-month low of $5.59 and a 12-month high of $9.05.
Haleon Announces Dividend
Analyst Upgrades and Downgrades
Several equities analysts recently commented on HLN shares. Sanford C. Bernstein started coverage on Haleon in a research report on Tuesday. They set an “outperform” rating for the company. Barclays boosted their target price on Haleon from GBX 360 ($4.47) to GBX 364 ($4.52) in a research report on Tuesday, January 31st. Argus upgraded Haleon from a “hold” rating to a “buy” rating in a research report on Thursday. Morgan Stanley upgraded Haleon from an “equal weight” rating to an “overweight” rating in a research report on Friday, January 6th. Finally, Investec started coverage on Haleon in a report on Thursday, February 23rd. They issued a “sell” rating for the company. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $364.00.
Haleon Profile
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements.
Featured Stories
- Get a free copy of the StockNews.com research report on Haleon (HLN)
- Costco Sales Disappoint, Markets Are Missing This Upside Driver
- First Republic Bank Is A Speculative Play, Here’s Why
- The WD-40 Company Bottoms With Reversal In Sight
- 3 Low-Cost Stock ETFs That Are Crushing It This Year
- FedEx Takes Flight; Analysts See More Gains Ahead
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.
